Zhi Tong Cai Jing·2025-09-09 04:01Core Viewpoint - Alibaba Health is experiencing significant stock price growth, attributed to its robust platform ecosystem and strong sales performance in health products and innovative drugs [1] Group 1: Financial Performance - Alibaba Health's stock rose by 6.32% to HKD 6.9, with a trading volume of HKD 1.099 billion [1] - HSBC Global Research has revised its revenue growth forecast for Alibaba Health for FY2026 from 9% to 15%, indicating improved profit margins due to a shift in revenue structure towards non-pharmaceuticals and enhanced profitability in first-party sales [1] - Citi has raised Alibaba Health's FY2026 revenue growth guidance to 10%-20% from the previous 5%-10%, and adjusted net profit growth guidance to 20%-30% from 10%-20%, driven by better-than-expected sales of original and innovative drugs, particularly GLP-1 medications [1] Group 2: Market Trends - The strong sales data from Alibaba Health and JD Health confirm the accelerating and sustainable trend of prescription drug outflow [1] - As original and innovative pharmaceutical companies expand new sales channels, online platforms like Alibaba Health and JD Health are positioned as the primary beneficiaries [1]